What does this research mean for the field?

Among patients with diabetes mellitus undergoing coronary procedures, the use of new antidiabetic drugs, particularly SGLT2 inhibitors, is associated with a significantly lower risk of contrast-associated acute kidney injury, whereas diuretics, sulfonylureas, and meglitinides are associated with an increased risk. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study examines how different glucose-lowering therapies affect the risk of contrast-associated acute kidney injury (CA-AKI) in patients with diabetes undergoing coronary procedures.

August 13, 2026DiabetologyOpen Access

Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus

View Full Paper

Ask AI

Bookmark

Authors

MVMonica VerdoiaInterventional / Structural Cardiology MNMatteo NardinInterventional / Structural Cardiology GCGiuseppe CilibertiUniversity of Bergamo

Discussion

Member takes

Implication

Retrospective analysis reveals varying effects of glucose-lowering therapies on acute kidney injury risk in diabetic patients undergoing coronary procedures, suggesting a safer approach with new...

Key Points

The study examines how different glucose-lowering therapies affect the risk of contrast-associated acute kidney injury (CA-AKI) in patients with diabetes undergoing coronary procedures.
Retrospective cohort study of 462 diabetic patients undergoing coronary angiography/angioplasty
Patients were categorized based on their glucose-lowering therapy, focusing on the use of new antidiabetic drugs (NAD)
Primary endpoint was CA-AKI occurrence within 72 hours post-exposure to iodinated contrast media.
10.4% of patients experienced CA-AKI, with lower rates in those using NADs (33.3% vs. 53.6%, p = 0.009)
Predictors of CA-AKI included diuretics (adjusted OR = 2.57 [1.33–4.97], p = 0.005) and the use of NADs (adjusted OR = 0.45 [0.24–0.86], p = 0.02)
Use of sulfonylureas and meglitinides increased CA-AKI risk (10.4% vs. 3.9%, p = 0.05).

Cite This Study

Verdoia et al. (2026) studied this question.

synapsesocial.com/papers/6a7d769b2b0e0cff3f64009a https://doi.org/10.3390/diabetology7080154

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reveals varying effects of glucose-lowering therapies on acute kidney injury risk in diabetic patients undergoing coronary procedures, suggesting a safer approach with new...

Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus

Discussion

Member takes

Implication

Key Points

Cite This Study

Glucose-Lowering Therapies and Contrast-Associated Acute Kidney Injury: Results from a Large Cohort of Patients with Diabetes Mellitus

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider